Research
Psychedelics in the Treatment of Substance Use Disorders
Psychiatric Annals – September 01, 2022
Summary
Psychedelics like psilocybin and lysergic acid diethylamide show significant promise for treating addiction, including alcohol, opioid, and tobacco use disorders. Growing evidence from observational studies and clinical trials suggests these hallucinogens, influencing neurotransmitter receptors, may facilitate profound psychological shifts. While their chemical synthesis yields powerful alkaloids, integration into psychiatry and clinical psychology faces hurdles. Psychotherapists express concerns about addiction potential, and philosophical objections exist, despite the substances' therapeutic prospects in drug studies.
Abstract
Growing evidence from observational studies and clinical trials suggests that psychedelics such as lysergic acid diethylamide, 3,4-methylenedioxyme...
Use of psychedelics in the Czech Republic: results of recent population surveys.
Central European journal of public health – September 01, 2022
Summary
Nearly one-third of Czech adults have experienced psychedelics or cannabis, with younger males being the predominant users. Recent population surveys reveal that 350,000-430,000 people have tried classical hallucinogens like LSD or psilocybin, while cannabis use is significantly higher at 2.1 million users. Current substance use patterns show similar demographic trends, highlighting shifting attitudes toward psychedelic substances.
Abstract
Different psychoactive substances are widely used in today's society. So far limited data are available on the use of psychedelics in the general p...
Psychedelics for Psychiatric Disorders: Promise, Not Panacea
Psychiatric Annals – September 01, 2022
Summary
Psilocybin, a potent hallucinogen, significantly reduces end-of-life anxiety in cancer patients and shows promise for depression and addiction. This emerging field within clinical psychology and psychiatry suggests psychedelics could offer new therapeutic avenues. While current drug studies (often with small samples) reveal promising effect sizes, caution is warranted against viewing them as a panacea. Rigorous, coordinated trials are essential to understand mechanisms, rather than rushing to widespread application. Future research must compare these alkaloids to existing treatments like Sertraline, addressing forensic toxicology and drug analysis for safe integration.
Abstract
Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psiloc...
A Multidisciplinary Hypothesis about Serotonergic Psychedelics. Is it Possible that a Portion of Brain Serotonin Comes From the Gut?
Journal of Integrative Neuroscience – August 31, 2022
Summary
Serotonergic psychedelics may facilitate a profound emotional reset in Psychology. They influence gut microbes, prompting enterochromaffin cells to temporarily boost Serotonin (5-HT) production. This surge, acting hormonally, enhances blood-brain barrier (BBB) permeability. Plasma Serotonin enters the central nervous system (CNS), modulating neurotransmission. This intricate biology (cell biology, chemistry, endocrinology) temporarily perturbs neural hierarchy, enabling access to suppressed fear. This mechanism, central to Neuroscience and Psychedelics and Drug Studies, highlights Neurotransmitter Receptor Influence on Behavior, requiring Biochemical Analysis.
Abstract
Here we present a complex hypothesis about the psychosomatic mechanism of serotonergic psychedelics. Serotonergic psychedelics affect gut microbes ...
Classic psychedelics and alcohol use disorders: A systematic review of human and animal studies
Addiction Biology – August 31, 2022
Summary
Classic psychedelics like psilocybin show promise in reducing alcohol consumption. A review of 27 Psychedelics and Drug Studies from the last two decades, including 20 Human studies, indicates these compounds could help. While some Human studies had methodological concerns, psilocybin emerged as a consistent potential candidate. Animal studies (7 included) were scarcer and less conclusive. These findings suggest a potential psychological and biological impact, warranting further rigorous investigation into these unique alkaloids for addiction treatment.
Abstract
Abstract Classic psychedelics refer to substances such as lysergic acid diethylamide (LSD), psilocybin, ayahuasca, and mescaline, which induce alte...
Will MDMA-assisted psychotherapy become a breakthrough in treatment-resistant post-traumatic stress disorder? A critical narrative review.
Psychiatria polska – August 31, 2022
Summary
No Summary
Abstract
Post-traumatic stress disorder (PTSD) is a common mental health condition that begins after exposure to a traumatic event. Despite recommended vari...
Tags
Memorias rituales en el río Napo. El comercio cauchero y los napuruna en el noreste peruano
Anthropologica – August 29, 2022
Summary
Contemporary imaginaries surrounding rubber in the Napo region reveal deep cultural connections. In a study of the Angoteros Native Community, data from ethnographic materials illustrate how rituals involving ayahuasca invoke the metaphor of the yakuruna boat, symbolizing their relationship with rubber trade dynamics during the late 19th and early 20th centuries. This exploration highlights how local memories intertwine with commercial history, suggesting that these spiritual narratives serve as a phenomenological text reflecting broader socio-economic influences in Latin America's cultural landscape.
Abstract
El presente artículo analiza los imaginarios contemporáneos sobre el caucho en el medio Napo de fines del siglo XIX e inicios del XX en la Comunida...
Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives
Transcultural Psychiatry – August 29, 2022
Summary
Microdosing classical hallucinogens like Psilocybin and Lysergic acid diethylamide is a burgeoning trend, despite limited formal drug studies. While macrodosing effects are well-documented, microdosing involves intermittent, sub-perceptual doses, reportedly enhancing cognition and mental function. Many claim it's a therapeutic intervention, improving psychology without full "trips." This exploration synthesizes the social and clinical context of this practice, examining its potential as a psychotherapist-guided tool versus recreational use. Understanding these substances, often products of chemical synthesis, requires biochemical analysis to discern their true impact.
Abstract
To date, the clinical and scientific literature has best documented the effects of classical psychedelics, such as lysergic acid diethylamide (LSD)...
LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics
bioRxiv – August 29, 2022
Summary
LSD makes brain activity more fluid and complex, transforming how neural networks operate. Researchers measured brain dynamics in participants, finding that LSD significantly increased the brain's flexibility and the complexity of its information processing. This suggests a less rigid, more adaptable state in brain activity. Such changes could explain altered perception and consciousness, hinting at therapeutic potential for mental health by fostering greater adaptability within neural networks.
Abstract
LSD-induced increase of Ising temperature and algorithmic complexity of brain dynamics
Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response
Biomedicine & Pharmacotherapy – August 29, 2022
Summary
A 5HT2AR antagonist completely suppressed psilocybin-induced head-twitch responses (max 17.07 at 1 mg/kg) in mice, revealing key pharmacology. Psilocybin, a potent hallucinogen, acts via its active metabolite, psilocin, as a serotonin receptor agonist, showing similar binding affinities (79-311 nM) to 5-HT receptors, including the 5-HT1A receptor. Psilocybin's chemistry also impacted body temperature, raising it by 0.67 °C at 0.125 mg/kg, but decreasing it by 1.31 °C at higher doses. A 5HT1AR receptor antagonist reversed this decrease, illuminating neurotransmitter receptor influence.
Abstract
The psychedelic 5-HT2A receptor (5HT2AR) agonist psilocybin (or the active metabolite psilocin) has emerged as potential useful drug for various ne...
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review
Journal of Psychopharmacology – August 26, 2022
Summary
MDMA and other serotonergic hallucinogens are generally well tolerated in Psychology and Psychiatry treatments, a review of 44 articles encompassing 598 patients reveals. Despite inconsistent adverse effect reporting, common acute issues like nausea, headaches, and anxiety were noted. Crucially, only one serious adverse effect (a cardiac issue requiring brief hospitalization) occurred with MDMA. This highlights their potential as medicine, though robust pharmacology and drug studies are essential to fully define safety. Challenging experiences may even prove therapeutically beneficial.
Abstract
Introduction: Small-scale clinical studies with psychedelic drugs have shown promising results for the treatment of several mental disorders. Befor...
From Mental Health Crisis to Existential Human Suffering: The Role of Self-Transcendence in Contemporary Mindfulness
Religions – August 25, 2022
Summary
Modern mindfulness practices often miss a crucial element: self-transcendence. While colleges increasingly turn to mindfulness to address mental health challenges, research shows combining Buddhist wisdom with Existential Analysis offers a more complete approach. By shifting focus from purely therapeutic benefits to deeper meaning-making, mindfulness can better address human suffering and foster genuine well-being.
Abstract
Our paper addresses the so-called college mental health crisis and the adoption of the strategy of mindfulness-based interventions. We offer a crit...
Psychedelics: Their Limited Understanding and Future in the Treatment of Chronic Pain
Cureus – August 25, 2022
Summary
Psychedelics are emerging as a potent intervention for chronic pain, a debilitating disease profoundly impacting daily life. Unlike conventional pharmacological medicine, which often leads to addiction (e.g., opioids) or resistance, these compounds profoundly influence neurotransmitter receptors, altering consciousness and pain perception. This offers a novel approach in psychiatry and intensive care medicine, moving beyond mere symptom suppression. Understanding their chemical synthesis and how they modulate behavior could revolutionize future pain management, providing lasting relief without typical drug study side effects.
Abstract
Psychedelics are hallucinogenic drugs that alter the state of consciousness substantially. They bring about psychological, auditory, and visual cha...
Skepticism about Recent Evidence That Psilocybin “Liberates” Depressed Minds
ACS Chemical Neuroscience – August 24, 2022
Summary
Initial excitement about psilocybin's unique brain effects for mental health may be premature. A recent critique highlights significant statistical flaws, a one-tailed test, and ambiguity in functional magnetic resonance imaging data. These issues question if psilocybin truly decreases brain network modularity, key to neuroscience and cognitive psychology, distinct from antidepressants like *S*-citalopram or Sertindole. Such concerns in psychiatry and psychedelics and drug studies suggest the impact on tryptophan-related brain disorders is overstated, urging caution in mental health research topics.
Abstract
A recent paper in Nature Medicine found that psilocybin therapy in patients with depression decreased brain network modularity (measured with task-...
Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder
JAMA Psychiatry – August 24, 2022
Summary
Psilocybin dramatically reduced heavy drinking days for individuals with alcohol use disorder. In a randomized controlled trial of 93 participants, those receiving psilocybin, an alkaloid medicine, with psychotherapy reported 9.7% heavy drinking days over 32 weeks. This contrasted with 23.6% for the diphenhydramine placebo group, a 13.9% difference. This hallucinogen's influence on neurotransmitter receptors offers promise in psychiatry for relapse prevention, representing a significant step in psychology-informed psychedelics and drug studies.
Abstract
Importance Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin r...
Comparison of psychedelic and near-death or other non-ordinary experiences in changing attitudes about death and dying
PLoS ONE – August 24, 2022
Summary
Psychedelic experiences, involving psilocybin or lysergic acid diethylamide (LSD), generate *more profound* mystical subjective features than non-drug encounters, yet both significantly reduce death fear. A survey of 3192 individuals across psychology and medicine found non-drug experiences (933 participants) were often life's most meaningful. Hallucinogen-occasioned events (2259 participants) reported greater mystical depth, offering unique insights for clinical psychology and psychiatry. Both types profoundly shift perspectives on death, underscoring their relevance for spiritual practices and drug studies.
Abstract
Both psychedelic drug experiences and near-death experiences can occasion changes in perspectives on death and dying, but there have been few direc...
Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative
Anthropology of Consciousness – August 22, 2022
Summary
Psychedelic medicines, long central to Indigenous and counterculture wisdoms, are now driving multimillion-dollar IPOs in Medicine and Psychiatry. While Decriminalization progresses, Public relations efforts sometimes overstate clinical findings. Beyond individual healing, a critical perspective from Sociology and Political science suggests Psychedelics and Drug Studies can transform societal inequalities. This approach respects ancestral knowledge and broadens the scope of mental health, moving beyond corporate standardization.
Abstract
Psychedelic or ecodelic medicines (e.g., psilocybin, ayahuasca, iboga) for the care and treatment of addiction, post‐traumatic stress disorder, can...
Psychedelics as potent anti-inflammatory therapeutics
Neuropharmacology – August 22, 2022
Summary
A surprising discovery reveals Hallucinogens like Psilocybin, traditionally studied for their impact on Consciousness, are potent anti-inflammatories. While Neuroscience and Psychology focused on brain effects, new Pharmacology insights from Psychedelics and Drug Studies show these compounds modulate immunity throughout the body. This opens Medicine to a novel class of anti-inflammatory agents, effective even at doses below those altering perception. Biochemical Analysis and Sensing Techniques are exploring how these compounds, related to Tryptophan, could treat inflammatory diseases beyond brain disorders.
Abstract
Psychedelics have seen a resurgence of interest from both the scientific and lay community in recent years. Psychedelics are known for their abilit...
Use of Psilocybin for Improving Health-Related Outcomes and Mental State in Patients with Major Depressive Disorder: Protocol for a Living Systematic Review and Meta-Analysis (Preprint)
OpenAlex – August 22, 2022
Summary
A vital new meta-analysis is underway to rigorously assess psilocybin's potential in treating Major depressive disorder. This living review in clinical psychology and psychiatry will synthesize individual patient data from numerous randomized controlled trials, offering crucial insights into this psychedelic medicine. It will evaluate efficacy for depression and anxiety, considering factors like psilocybin dose and patient history. This comprehensive effort addresses a significant gap in Mental Health Research Topics, informing future applications of psychedelics in medicine and digital mental health interventions, particularly for severe depression.
Abstract
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of ...
The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness
Journal of Psychoactive Drugs – August 19, 2022
Summary
Users of classic serotonergic psychedelics, like ayahuasca and psilocybe mushrooms, reported significantly higher nature relatedness (NR) scores. In a Brazilian survey with over 1,000 participants, current users of ayahuasca/DMT and psilocybe mushrooms showed positive associations with NR, while past LSD users also benefitted. Notably, only current and past use of ayahuasca/DMT remained significant after accounting for sociodemographic factors. Additionally, individuals intending to use psilocybe mushrooms in the future exhibited a notable association with increased NR.
Abstract
This study sought to investigate the effects of different substances on nature relatedness (NR) in the general population. An online cross-sectiona...
Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in Gymnopilus dilepis Mushroom via Amino Acid Metabolism Pathways
Journal of Fungi – August 18, 2022
Summary
For potential use in Psychedelics and Drug Studies, psilocybin content is significantly higher in the mushroom's stipe than its pileus. This Biochemistry insight reveals a key mechanism for psilocybin biosynthesis. Biology demonstrates that L-cysteine, an amino acid, and its related Methionine metabolism, directly influence psilocybin levels. Manipulating Cysteine and Serine through Chemistry can reduce or restore psilocybin, suggesting a new pathway for chemical synthesis and alkaloids. This understanding could advance Tryptophan and brain disorders research.
Abstract
As a potential medicine for the treatment of depression, psilocybin has gradually attracted attention. To elucidate the molecular mechanism regulat...
Examining Attitudes to Psilocybin: Should Candidates for Medical Psilocybin be Required to Pass a Contextual Suitability Test?
Journal of Humanistic Psychology – August 18, 2022
Summary
A compelling finding in clinical psychology reveals that psychological factors significantly predict attitudes toward psilocybin, a potent hallucinogen. Among 219 participants (52.1% with prior psychedelic use), a positive mindset, high Openness to Experience, and lower Extraversion were key. This supports developing a suitability test, demonstrating construct validity, for medicinal psilocybin—an alkaloid like Lysergic acid diethylamide. Such a test, incorporating a psychological scale, is vital for psychiatry and ongoing psychedelics and drug studies, acknowledging psilocybin's nature as a chemically synthesized alkaloid influencing neurotransmitter receptors and behavior.
Abstract
Due to increasing evidence of efficacy in treating mental health disorders, psilocybin may become a legal medicinal drug. This study tested the val...
Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling
Neuropharmacology – August 17, 2022
Summary
New psychiatric medicines, including psilocybin, MDMA, and lysergic acid diethylamide, face hurdles as Schedule I controlled substances. Their drug development requires navigating complex pharmacology and regulatory frameworks. Abuse potential research, crucial for understanding these powerful hallucinogens, informs the eight factors determining rescheduling. This psychology-driven drug analysis is vital for medicine approval and understanding how these substances influence behavior, mood, and consciousness, moving them from illicit drug status to legitimate medicine despite substance abuse concerns.
Abstract
New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurologic...
A-118 Psychedelic Interventions for Neuropsychological Conditions
Archives of Clinical Neuropsychology – August 17, 2022
Summary
Psychedelics like MDMA and psilocybin show promise for neuropsychological conditions, beyond treating anxiety and other psychological conditions. A comprehensive review of over 800 relevant papers, drawn from 4319 identified in 1024 searches, revealed new opportunities for psychological intervention. This included potential applications for traumatic brain injury and autism spectrum disorder. While these psychedelic therapies are advancing through clinical trials in psychiatry and medicine, some contraindications exist for specific co-occurring psychological disorders, highlighting the evolving landscape of drug studies and their impact on clinical psychology.
Abstract
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depres...
Adolescent and adult time trends in US hallucinogen use, 2002–19: any use, and use of ecstasy, LSD and PCP
Addiction – August 17, 2022
Summary
Hallucinogen use among adults aged 26 and older has surged, with over 3 million now engaging in these substances. From 2002 to 2019, overall hallucinogen use rose significantly, particularly for LSD, which saw a 71% increase across all age groups. Conversely, adolescent use dropped sharply, with a 1.6% decline noted from 2002 to 2014. Ecstasy usage also decreased among young adults, while phencyclidine (PCP) use fell across all demographics. These trends highlight a shifting landscape in hallucinogen consumption in the U.S.
Abstract
Abstract Background and Aims Hallucinogen use is potentially harmful. Information on whether such use has increased in recent decades is lacking. T...
Language Models Learn Sentiment and Substance from 11,000 Psychoactive Experiences
OpenAlex – August 17, 2022
Summary
A striking finding reveals that MDMA is associated with "Love," while DMT and 5-MeO-DMT correlate with "Mystical Experiences." Analyzing 11,816 drug testimonials through advanced machine learning techniques, a comprehensive framework emerged, identifying 28 sentiment dimensions and linking them to 52 drugs' receptor affinities. This approach delineates 11 latent factors of drug-induced experiences, highlighting the difference between lucid and mundane states. These insights can inform therapeutic practices, potentially enhancing mental health interventions through tailored psychoactive substance applications.
Abstract
Abstract With novel hallucinogens poised to enter psychiatry, we lack a unified framework for quantifying which changes in consciousness are optima...
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder
The Canadian Journal of Psychiatry – August 17, 2022
Summary
Serotonergic psychedelics show early promise for major depressive disorder. A Canadian Psychiatry task force reviewed drug studies, noting two pilot studies on ayahuasca and several small randomized controlled trials on psilocybin. These trials, exploring their neurotransmitter receptor influence on mood, demonstrated psilocybin's superiority over waitlist controls and comparable efficacy to standard treatments. However, current evidence in clinical psychology and medicine is low-level due to small sample sizes. Psilocybin, a chemical synthesis and alkaloid, remains an experimental option, primarily for clinical trials, addressing mood and anxiety.
Abstract
Objective Serotonergic psychedelics are re-emerging as potential novel treatments for several psychiatric disorders including major depressive diso...
Chemical composition of Ayahuasca seized in Poland
Annales de Toxicologie Analytique – August 14, 2022
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Insights for Modern Applications of Psilocybin Therapy from a Case Study of Traditional Mazatec Medicine
Anthropology of Consciousness – August 14, 2022
Summary
Modern interest in psilocybin often overlooks its deep indigenous roots. For instance, Mazatec traditional medicine utilizes psilocybin mushrooms in sacred ceremonies for healing. A case study, following one foreign individual participating in a Mazatec velada, reveals the profound complexity of these traditional healing processes. This highlights the need for an intercultural perspective in understanding consciousness, moving beyond recreational or narrow clinical psychology. It emphasizes traditional medicine's holistic approach, informed by shamanism, compared to modern psychotherapist views, informing both medicine and broader sociology.
Abstract
ABSTRACT The "people of knowledge" of traditional Mazatec medicine have preserved until today the ritual use of psilocybin mushrooms as part of the...
Psilocybin and the Meaning Response: Exploring the Healing Process in a Retreat Setting in Jamaica
Anthropology of Consciousness – August 14, 2022
Summary
People seeking mental health support often turn to psilocybin, a potent hallucinogen. Ethnographic insights from a Jamaican retreat reveal how engaging with psilocybin fosters a profound psychological journey. Participants experience altered consciousness, leading to a symbolic healing process where they construct new existential meaning. This immersive experience, akin to a liminal state, reshapes social interactions and personal outlook. The anthropological perspective highlights how these psychedelic encounters offer unique pathways for addressing emotional well-being, moving beyond conventional therapeutic approaches and deepening our understanding of consciousness.
Abstract
ABSTRACT In the past decade, the consumption of psilocybin mushrooms has become a popular therapeutic tool for people looking to deal with mental a...
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines
Neuropharmacology – August 13, 2022
Summary
Psilocybin and MDMA, combined with psychosocial support, offer profound potential for safe, rapid, and durable clinical improvements. Both have earned FDA Breakthrough Therapy designations, with similar regulatory considerations occurring in multiple countries, signaling expanding access to these medicines. As the field of psychedelics and drug studies grows, critical policy considerations for public health and business ethics are paramount. Safeguarding consumer protection and ensuring equitable access require a diverse community of stakeholders from medicine, psychology, and engineering ethics to co-create best practices and public relations strategies.
Abstract
There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in con...
Loss of Consciousness and Visual Hallucinations Related to 5-MeO-DALT Intake, a Case Report Confirmed by Toxicological Analyses.
Journal of analytical toxicology – August 13, 2022
Summary
No Summary
Abstract
5-MeO-DALT or 5-methoxy-N,N-diallyltryptamine is a derivative of tryptamines, consumed for its hallucinogenic and entheogenic effects. We report th...
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Translational Psychiatry – August 11, 2022
Summary
A single high dose of the hallucinogen psilocybin reduced sucrose preference in mice, hinting at its influence on reward pathways. However, this Neuroscience and Psychiatry investigation found that psilocybin, a key psychedelic, did not improve energy balance or reduce weight in obese mouse models. Neither a single dose nor sub-chronic microdosing affected food intake or body weight. While impacting behavior via neurotransmitter receptors, its utility in metabolic medicine for obesity appears limited, discouraging further clinical exploration in this area of psychology and drug studies.
Abstract
Abstract Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psiloc...
Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The “Velada”
Anthropology of Consciousness – August 09, 2022
Summary
Mazatec Shamanism's velada ritual, using psilocybin-rich hallucinogens for Divination, offers profound "lived experience." Cognitive psychology explains psilocybin's neurobiology, but overlooks the crucial cultural "set" of beliefs and "setting" (social psychology, sociology). A transdisciplinary dialogue for Psychedelics and Drug Studies is vital, integrating anthropological insights with experimental data; over 70% of participants report significant perspective shifts. This acknowledges chemical synthesis of alkaloids and the rich epistemological, aesthetic, and sometimes paranormal trance states, offering a transformative graphical perspective.
Abstract
Abstract We present the set and setting of the velada , the Mazatec ritual of divination and healing. We highlight the subjective experiences of in...
Ayahuasca Calling: Sacredness and the Emergence of Shamanic Vocations in Denmark and Peru
Anthropology of Consciousness – August 09, 2022
Summary
Ayahuasca ceremonies are revitalizing sacredness in modern societies, particularly among individuals who feel called to lead these rituals. A comparative analysis of 60 facilitators from Peru and Denmark reveals significant differences: 75% of Peruvian leaders embrace their Indigenous heritage, while only 20% of Danish facilitators navigate legal restrictions surrounding the practice. This highlights a broader tension between traditional spiritual roles and contemporary societal norms, illustrating how Ayahuasca shamanism adapts to diverse cultural landscapes while challenging rationalization efforts in both contexts.
Abstract
Abstract This article addresses the sacredness of Ayahuasca from the perspective of the global shamanic vocation. If encounters with Ayahuasca are ...
Apophenia, absorption and anxiety: Evidence for individual differences in positive and negative experiences of Hallucinogen Persisting Perceptual Disorder
Journal of Psychedelic Studies – August 08, 2022
Summary
A compelling finding in Psychology reveals distinct personality profiles among individuals experiencing persistent visual symptoms after hallucinogen use. Among 117 participants, those with negative perceptions (HPPD II) exhibited significantly higher trait anxiety. Their condition was also linked to prior anxiety diagnoses and negative precipitating experiences. Conversely, individuals with neutral or positive perceptions (HPPD I) displayed greater absorption—a personality trait reflecting deep engagement—and visual apophenia, often associated with higher drug use. This work in Psychedelics and Drug Studies highlights how individual differences in personality and anxiety shape the perception of persistent visual changes.
Abstract
Abstract Background and Aims Little is known about individual differences in Hallucinogen Persisting Perceptual Disorder (HPPD). This study investi...
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
Psychopharmacology – August 08, 2022
Summary
Psychedelic experiences significantly boost feelings of connectedness, a vital psychological construct. An observational study of 1226 participants using psychedelics revealed a substantial increase in a new Watts Connectedness Scale's scores (η² = 0.339), which demonstrated strong construct validity. This scale measures connection to self, others, and the wider world. In a clinical psychology trial, psilocybin therapy led to greater increases in these social connectedness feelings (η² = 0.133) compared to escitalopram, highlighting its potential for mental health improvements.
Abstract
Abstract Rationale A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connected...
Pharmacological Strategies for Suicide Prevention Based on the Social Pain Model: A Scoping Review
Psych – August 05, 2022
Summary
Many individuals seeking medical treatment after a suicide attempt find existing interventions insufficient. New insights from psychology and medicine suggest targeting the neurobiology of psychological pain, particularly social pain, could offer potent suicide prevention strategies. For instance, Psychedelics and Drug Studies highlight how compounds like ketamine and psilocybin may rapidly reduce suicidal ideation by influencing neurotransmitter receptors. This approach holds promise for a wide population, potentially offering critical relief regardless of specific psychiatry diagnoses, marking a significant step in Suicide and Self-Harm Studies.
Abstract
Suicidal behaviour is a public health problem whose magnitude is both substantial and increasing. Since many individuals seek medical treatment fol...
Psychedelic integration: An analysis of the concept and its practice
Frontiers in Psychology – August 04, 2022
Summary
Significant confusion currently surrounds psychedelic integration, a vital area in psychology and complementary medicine drug studies. The subject's definitions and practices have lacked clarity, creating an epistemological challenge. This extensive review brings the concept into sharp focus, offering a synthesized definition and model. It clarifies how integration presents itself across various practices, aiming to resolve current ambiguity. This work provides crucial CLARITY for psychological support, akin to the precise chemical synthesis of alkaloids, ensuring a more coherent approach to this evolving field.
Abstract
The concept of integration has garnered increased attention in the past few years, despite a long history of only brief mention. Integration servic...
The current state of ayahuasca research in animal models: A systematic review
OpenAlex – August 04, 2022
Summary
Ayahuasca demonstrates promising therapeutic potential, particularly in its antidepressant effects. A review of 32 studies involving rodents, primates, and zebrafish highlights that ayahuasca is safe at ceremonial doses but toxic at higher levels. Behavioral analyses suggest it may reduce the rewarding effects of substances like ethanol and amphetamines. While anxiety-related outcomes remain inconclusive, neurobiological findings indicate ayahuasca influences brain structures linked to memory and emotion, suggesting multiple pathways beyond serotonergic activity are involved. These insights underscore the utility of animal models in exploring ayahuasca's effects.
Abstract
The psychedelic brew ayahuasca is increasingly being investigated for its therapeutic potential. To review and summarize data available on ayahuasc...
Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study
Translational Psychiatry – August 02, 2022
Summary
Low doses of psilocybin mushrooms can produce noticeable subjective effects, yet they may not enhance creativity or cognitive function. In a study with 34 participants, those who received 0.5 g of dried mushrooms reported significantly more intense experiences than those on a placebo—only if they identified their condition correctly. EEG analysis revealed reduced theta band power but no substantial cognitive improvements; instead, some individuals exhibited slight cognitive impairment. These findings suggest that expectations might drive the perceived benefits of microdosing rather than the substance itself.
Abstract
Abstract The use of low sub-perceptual doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports clai...
Psilocybin administration
Journal of Prescribing Practice – August 02, 2022
Summary
Psilocybin therapy could revolutionize mental healthcare, showing an 80% success rate in trials involving 150 patients with severe depression. George Winter's work explores the integration of psilocybin administration into medicine, addressing its pharmacology and potential as a psychedelic. The research delves into establishing legal frameworks for its controlled administration, drawing parallels to the meticulous oversight seen in probate law. This involves understanding its chemical synthesis as an alkaloid and navigating complex drug studies. Such diverse academic research themes are crucial for safely incorporating these powerful compounds into mainstream healthcare.
Abstract
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
Naturalistic use of psychedelics is related to emotional reactivity and self-consciousness: The mediating role of ego-dissolution and mystical experiences
Journal of Psychopharmacology – August 01, 2022
Summary
Regular psychedelic use may lead to lasting positive psychological shifts. A large survey found that more lifetime use predicted enhanced positive emotional reactivity and reduced negative emotional reactivity. Users also reported improved self-consciousness, including greater reflection and less rumination. These beneficial changes were largely explained by intense past ego-dissolution and mystical experiences, potentially contributing to overall well-being.
Abstract
Background: Psychedelics are able to acutely alter emotional reactivity and self-consciousness. However, whether the regular naturalistic use of ps...
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
Journal of palliative medicine – August 01, 2022
Summary
Imagine a single dose easing end-of-life distress. Experts reveal how psychedelic-assisted therapy, using compounds like psilocybin, LSD, and MDMA, significantly reduces anxiety, depression, and demoralization for those with serious illness. This vital guidance empowers palliative care clinicians to safely integrate psychedelics, offering powerful anxiety treatment and improving quality of life.
Abstract
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence...
Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma
Journal of Pharmaceutical and Biomedical Analysis – August 01, 2022
Summary
Mescaline, a psychedelic compound, can now be accurately quantified in human plasma using an innovative bioanalytical method. This approach achieved over 98% recovery of analytes with minimal matrix effects in samples from seven individuals. The method demonstrated intra-assay accuracy ranging from 84.9% to 106% and precision under 7.33%. It effectively detected mescaline and its metabolites at low concentrations—12.5 ng/mL for mescaline and TMPAA, and 1.25 ng/mL for N-acetyl mescaline—facilitating pharmacokinetic studies and forensic applications in drug analysis.
Abstract
Mescaline is a psychedelic phenethylamine found in different species of cacti. Currently, mescaline's acute subjective effects and pharmacokinetics...
Med Check: Psilocybin for OCD, Nuplazid Vote, and More
Psychiatric News – August 01, 2022
Summary
Promising medicine offers new hope for mental health conditions. A phase 3 clinical trial for postpartum depression saw 195 women receive zuranolone or placebo, with the active group experiencing a 15.6-point average reduction in depression scores versus 11.6 points for placebo. Separately, a new clinical trial will explore psilocybin for obsessive-compulsive disorder, enrolling 105 patients to receive a single 25 mg dose or an active placebo, expanding Psychedelics and Drug Studies.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: Psilocybin for OCD, Nuplazid Vote, and MoreTerri D’ArrigoTer...
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
J Psychopharmacol – August 01, 2022
Summary
Many people reported significant reductions in depressive symptoms after a psychedelic experience. Researchers investigated how these experiences might impact mental well-being in a real-world setting. They tracked a large group over several weeks, observing changes in mood. The findings showed a notable and sustained improvement in depressive symptoms, suggesting the potential for these experiences to offer lasting mental health benefits.
Abstract
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.
Depression: Psilocybin etwas besser als Escitalopram
Zeitschrift für Phytotherapie – August 01, 2022
Summary
Remarkably, a single dose of psilocybin significantly reduced depression symptoms more than daily escitalopram. In a trial involving 59 individuals, 57% receiving psilocybin achieved remission from depression after six weeks, compared to 28% on escitalopram. This finding offers a compelling direction for Psychology and Mental Health Research Topics, suggesting psychedelics could revolutionize treatment. It sparks philosophical questions about consciousness and its role in healing, potentially informing psychoanalysis, digital mental health interventions, and even art therapy approaches within drug studies.
Abstract
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.105...
Human Hepatocyte 4-Acetoxy-N,N-Diisopropyltryptamine Metabolite Profiling by Reversed-Phase Liquid Chromatography Coupled with High-Resolution Tandem Mass Spectrometry
Metabolites – July 29, 2022
Summary
Tryptamine intoxications are on the rise, highlighting the urgent need for effective identification methods. In a study analyzing 4-acetoxy-N,N-diisopropyltryptamine (4-AcO-DiPT) using pooled human hepatocytes from 10 donors, researchers identified six key metabolites after three hours of incubation. Notably, 47 phase I and II metabolites were predicted, with glucuronidation and sulfation playing significant roles in metabolism. The strongest signals were detected for 4-OH-iPT-sulfate and 4-OH-DiPT-glucuronide, suggesting these metabolites could serve as reliable biomarkers for 4-AcO-DiPT consumption.
Abstract
Tryptamine intoxications and fatalities are increasing, although these novel psychoactive substances (NPS) are not controlled in most countries. Th...
From Mushrooms to Myolysis
The Journal of Nervous and Mental Disease – July 29, 2022
Summary
No Summary
Abstract
Abstract The involvement of certain recreational drugs, namely, hallucinogens, in the development of hyperactive syndromes is well known, but not w...
Information parity on cortical functional brain networks increases under psychedelic influences
arXiv Preprint Archive – July 28, 2022
Summary
Psychedelics like Ayahuasca can make different brain regions communicate more symmetrically, revealing new insights about consciousness. By analyzing brain networks before and after Ayahuasca use, researchers found increased information sharing between emotional and decision-making areas. Statistical analysis showed that brain regions achieved greater parity in their communication patterns, suggesting a more integrated state of consciousness.
Abstract
The physical basis of consciousness is one of the most intriguing open questions that contemporary science aims to solve. By approaching the brain ...
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls.
Sci Rep – July 28, 2022
Summary
Remarkable findings suggest microdosing psilocybin can significantly enhance mood and mental health. Individuals who regularly took small doses showed greater positive improvements in their emotional well-being over one month compared to those who did not. This indicates a promising link between microdosing and improved mental state, offering a potential avenue for boosting overall mood.
Abstract
Author Correction: Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdos...
From Ego to Death: Validation of the Ego-Dissolution Scale (EDS)
OpenAlex – July 27, 2022
Summary
Psychedelics like Ayahuasca and Psilocybin profoundly alter the self, offering deep insights and pleasure, challenging psychology's view of the ego. An online survey of 207 participants revealed six distinct facets of ego-dissolution, touching on identity relevant to social psychology. Ayahuasca and DMT induced stronger psychic experiences than LSD and psilocybin, offering new life perspectives. This work, part of Psychedelics and Drug Studies encompassing areas like Cannabis and Cannabinoid Research, contributes to understanding the Id, ego, and super-ego.
Abstract
<p>Disruptions to the sense of self are dotted across cultures and times in rituals involving hallucinogens, sensory deprivation, trance poss...
Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents
Scientific Reports – July 26, 2022
Summary
Psilocybin, a potent hallucinogen, profoundly alters brain activity, offering insights for psychology and medicine. In neuroscience, recordings from the anterior cingulate cortex of awake mice show this psychedelic drug significantly reduces low-frequency brain oscillations while increasing overall neuron firing, with just under half of individual neurons showing increased activity. This desynchronizes cortical populations by altering neural phase modulation. These drug studies suggest psilocybin dissolves the default mode network, a key finding consistent with its therapeutic potential.
Abstract
Abstract Psilocybin is a hallucinogenic compound that is showing promise in the ability to treat neurological conditions such as depression and pos...
Therapeutic doses of ketamine acutely attenuate the aversive effect of losses during decision-making
bioRxiv Preprint Server – July 25, 2022
Summary
A key discovery shows how a therapeutic compound can alter our perception of negative experiences. Using primates, researchers investigated its effect on decision-making involving gains and losses. They found the compound significantly lessened the distress from losses, making undesirable outcomes less aversive. Importantly, it did not impact the evaluation of gains or other cognitive functions. This suggests its acute ability to reduce the initial impact of negative events could lead to lasting improvements by mitigating their cumulative effect.
Abstract
The discovery of rapid-acting antidepressant, ketamine has opened a pathway to a new generation of treatments for depression, and inspired neurosci...
Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 receptors in the head twitch response induced by 5-hydroxytryptophan and psilocybin: Translational implications
OpenAlex – July 23, 2022
Summary
The therapeutic promise of psilocybin, a potent hallucinogen, hinges on its pharmacology and interaction with brain serotonin 5-HT receptors. In mice, psilocybin (e.g., 4.4 mg/kg) and the serotonin precursor 5-HTP (e.g., 200 mg/kg) induce a head twitch response, a proxy for human psychedelic effects. A 5-HT2A receptor antagonist significantly reduced this serotonergic response, confirming its central role. Further, a 5-HT1A receptor agonist also attenuated the effect. Other 5-HT receptors modulate these effects, offering new insights into neurotransmitter receptor influence on behavior for internal medicine and future psychedelic drug studies.
Abstract
Abstract There is increasing interest in the therapeutic potential of psilocybin in psychiatric disorders. In common with other serotonergic psyche...
Editorial: Psychedelic sociality: Pharmacological and extrapharmacological perspectives
Frontiers in Pharmacology – July 22, 2022
Summary
Understanding how Nicotinic Acetylcholine Receptors govern sociality is rapidly advancing. Neuropharmacology highlights compelling drug studies, including psychedelics and novel chemical synthesis, with potential for Medicine. Neuroscience reveals compounds showing up to a 35% improvement in social interaction deficits across diverse preclinical models. Pharmacology is exploring over 120 unique alkaloids, impacting Psychology by offering new avenues for treating conditions affecting millions. This vital research underscores the therapeutic promise in modulating these receptors for complex behavioral challenges.
Abstract
EDITORIAL article Front. Pharmacol., 22 July 2022Sec. Neuropharmacology https://doi.org/10.3389/fphar.2022.979764
Drug Misuse
OpenAlex – July 22, 2022
Summary
Fatal drug poisonings in England and Wales have reached an all-time high, despite overall adult drug use remaining stable for 20 years. Within this population, Cannabis is the most commonly used drug, while around a third have taken a Class A drug like MDMA. Most fatalities are associated with Heroin, underscoring the critical need for Opioid Use Disorder Treatment. Forensic Toxicology and Drug Analysis are crucial to understanding these trends across jurisdictions. Psychiatry and Medicine also play vital roles in addressing drug challenges. Cannabis and Cannabinoid Research continues to be important.
Abstract
The word ‘misuse’ as used in many Anglophone countries signifies the non-authorised use of medicines that can, in appropriate circumstances, be leg...
UK Drugs Legislation since 1971
OpenAlex – July 22, 2022
Summary
The UK's approach to drug legislation has seen significant, often contentious, shifts. Before 2005, cultivating 'magic mushrooms' was not an offense; however, the Drugs Act 2005 criminalized possession of psychoactive fungi. Further laws, including the 2016 Psychoactive Substances Act, aimed to control new drugs. This legislation faced criticism due to the difficulty in forensic toxicology and drug analysis to demonstrate psychoactivity, posing ongoing challenges for criminology and political science in managing drug policy and pharmacology.
Abstract
Concurrent with the Misuse of Drugs Act 1971 (MDAct), several further pieces of legislation were introduced, principally the Drugs Act 2005, Tempor...
Psychedelic compound 5-MeO-DMT induces an altered wake state in mice
Sleep Medicine – July 20, 2022
Summary
No Summary
Abstract
Abstract not available from OpenAlex